Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
J Biol Regul Homeost Agents ; 9(4): 146-9, 1995.
Article in English | MEDLINE | ID: mdl-8844339

ABSTRACT

At present, it is known that there are two main mechanisms responsible for cancer-related immunosuppression, mediated by macrophages and by TH2 lymphocytes. The relation existing between macrophage- and TH2-mediated immunosuppression still remains to be understood. The present study was performed in an attempt to establish which is the correlation existing in cancer patients between IL-10 and neopterin levels, which reflect TH2- and macrophage-mediated suppressive events, respectively. The study included 40 solid tumor patients and 60 healthy subjects as controls. Serum concentrations of neopterin and IL-10 were measured by the RIA method and by an immuno-enzymetric assay, respectively. Because of its possible production both by TH2 and macrophages, serum levels of IL-6 were also determined. Neopterin, IL-10 IL-6 mean concentrations were significantly higher in cancer patients than in controls. Mean values of both neopterin and IL-6 were significantly higher in metastatic patients than in those with locally limited disease. IL-10 mean levels were also significantly higher in patients with metastatic disease. IL-6 levels were significantly correlated with those of neopterin, whereas no correlation was found between neopterin and IL-10 values. This preliminary study would suggest that macrophage- and TH2-mediated immunosuppression may occur independently in solid tumors, and that it becomes more evident with disease progression.


Subject(s)
Biopterins/analogs & derivatives , Interleukin-10/blood , Interleukin-6/blood , Macrophages/physiology , Neoplasms/immunology , Adult , Aged , Biopterins/blood , Disease Progression , Female , Humans , Male , Middle Aged , Neoplasm Metastasis/immunology , Neoplasms/etiology , Neopterin , Th2 Cells/physiology
2.
J Chemother ; 2(6): 384-9, 1990 Dec.
Article in English | MEDLINE | ID: mdl-2093111

ABSTRACT

Twenty patients undergoing tonsillectomy were treated with a peroral administration of 600 mg of miocamycin every 12 hours for 4 days. On the 5th day, after a last administration of a dose of 600 mg the ablation of the tonsils was carried out on groups of 4 subjects, each one at the following times after oral intake of the drug: 2, 4, 6, 8, 12 h. Twenty-nine patients, admitted to hospital to undergo lung resection were treated with peroral administration of miocamycin in accordance with the above mentioned dose scheme. The operation was carried out on groups of 5 subjects, each on the fifth day at the following times after the last administration: 2, 3, 4, 6, 8 and 12 h (4 subjects). Simultaneously blood was withdrawn for the determination of miocamycin in serum. Miocamycin was measured by a microbiological procedure using Sarcina lutea ATCC 9341. The highest levels of miocamycin were observed after 2h in tonsils (3.2 +/- 0.82 mg/kg) and serum (1.3 +/- 0.33 mg/l). After 12h miocamycin proved to be still measurable in the tissue (0.12 +/- 0.05 mg/kg), whereas it was not detected in serum. In pulmonary tissue, the highest levels of miocamycin were likewise identified at the 2nd hour (2.82 +/- 0.59 mg/kg), simultaneously with the highest serum levels (2.3 +/- 0.61 mg/l). At the 12th hour miocamycin could still be dosed in 3 tissue samples, with values between 0.1 and 0.2 mg/kg and was found just at dosing limits in only one serum sample.


Subject(s)
Lung/metabolism , Miocamycin/pharmacokinetics , Palatine Tonsil/metabolism , Adolescent , Aged , Child , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Miocamycin/administration & dosage , Tonsillectomy
3.
Acta Otolaryngol ; 111(4): 756-61, 1991.
Article in English | MEDLINE | ID: mdl-1950539

ABSTRACT

A group of 18 patients, before undergoing otoplastic surgery, was treated with miocamycin 600 mg in a single dose; middle ear tissue samples were collected at 2, 3, 4 and 6 h. A group of 20 patients suffering from secretory otitis media (SOM) was also treated with 600 mg of miocamycin in a single dose; collections of middle ear fluid (MEF) were performed at 1, 2, 4 and 6 h. Blood withdrawals from all patients occurred at the same time intervals. The miocamycin determination was performed by means of a microbiological method employing Sarcina lutea ATCC 9341. The highest serum levels (1.06 +/- 0.13 mg/l) were found at 2 h in the group from which middle ear mucosa had been withdrawn and at 1 h (2.2 +/- 0.5 mg/l) in the group from which the MEF had been collected; at 6 h miocamycin could be determined in both groups, with values ranging from 0.1 to 0.2 mg/l. In middle ear mucosa the miocamycin concentration was 1.52 +/- 0.27 mg/kg at 2 h and 0.2 +/- 0.09 mg/kg at 6 h. In MEF, the miocamycin concentration was 2.1 +/- 0.27 mg/l at 1 h and 0.24 +/- 0.05 mg/l at 6 h. The miocamycin concentration determined at 1 h in MEF was virtually equal to that in serum at the same time. At the following experimental times of withdrawal, the miocamycin concentration in mucosa specimens, as well as in MEF samples, proved to be markedly higher than values simultaneously found in serum.


Subject(s)
Ear, Middle/chemistry , Miocamycin/pharmacokinetics , Otitis Media with Effusion/metabolism , Adult , Aged , Female , Humans , Male , Middle Aged , Miocamycin/analysis , Miocamycin/blood , Mucous Membrane/chemistry , Otitis Media with Effusion/drug therapy , Time Factors
4.
Clin Ter ; 128(1): 21-5, 1989 Jan 15.
Article in Italian | MEDLINE | ID: mdl-2525988

ABSTRACT

After comparing the referral diagnoses of women with vaginitis sen to our cervicovaginitis out-patient clinic at the Ospedale Fatebenefratelli e Oftalmico of Milan with the subsequent bacteriological diagnoses, the Authors emphasize that treatment for the different types of vaginitis must be prescribed only after accurate and thorough bacteriological examination in order to avoid inadequate treatment and unnecessary discomfort to the patients.


Subject(s)
Vaginitis/etiology , Candidiasis, Vulvovaginal/diagnosis , Chlamydia Infections/diagnosis , Female , Gardnerella vaginalis , Haemophilus Infections/diagnosis , Humans , Trichomonas Vaginitis/diagnosis , Vaginitis/microbiology
9.
Boll Ist Sieroter Milan ; 59(4): 348-58, 1980 Sep 30.
Article in Italian | MEDLINE | ID: mdl-6258612

ABSTRACT

The Authors report a case-list of 395 patients vaginal specimens who were never treated with chemo-antibiotic therapy. Cell dysplastic impairments were found in 213 cases. About these dysplastic alterations, 133 are of slight type, 53 intermediate type and 27 are in advanced phase. We can say, about the last 27 cases, that the concomitance of pH greater than 6.1 in 67% of the cases and the absence of Lactobacillus acidophilus in 81.4% of the cases is not casual. Furthermore, we can notice that vaginal pH suffers an increase in dysplastic patients with a smaller colonization with Lactobacillus acidophilus that, in dysplastic advanced phase is absent in 81.4% of the cases. It is also to remark a significant increase of cases Trichomonas-positive and Mycoplasmas-positive in dysplastic patients, as compared with normal women. The results of the case-list, even if preliminary, seem to be indicative for an evolution of the studies on the relationship between uterine cervix cells and Mycoplasmas and eventual possibility the Mycoplasmas can act as carriers of oncogenic viruses such as Herpes and Papova Virus.


Subject(s)
Cervix Uteri/abnormalities , Mycoplasma Infections/diagnosis , Animals , Anti-Bacterial Agents/therapeutic use , Carrier State , Cervix Uteri/pathology , Female , Herpesviridae Infections/etiology , Humans , Hydrogen-Ion Concentration , Lactobacillus acidophilus , Mycoplasma Infections/drug therapy , Papillomaviridae , Polyomaviridae , Trichomonas Infections/diagnosis , Tumor Virus Infections/etiology
10.
Ital J Gastroenterol Hepatol ; 29(3): 262-6, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9646219

ABSTRACT

BACKGROUND: Selective intestinal decontamination has been proposed to prevent bacterial infection in cirrhosis. AIMS: To evaluate the efficacy of ciprofloxacin as selective intestinal decontaminant. PATIENTS AND METHODS: Quantitative microbiological studies on serial faeces were carried out in 15 cirrhotic patients. Ciprofloxacin was given orally at the starting dose of 250 mg every 12 hours for 7 days followed by a single dose of 250 mg/day from day 7 to day 14 and 125 mg/day for the next 3 weeks. Total stool samples were examined in basal conditions and on days 7, 14, 21, 28 and 35 of treatment and 3 and 7 days after treatment withdrawal. RESULTS: Gram-negative flora was completely eliminated in all patients by ciprofloxacin given at doses of 500 and 250 mg/day. When the drug was tapered to 125 mg/day, Escherichia coli reappeared in stools of 7 patients (antibiotic-resistant in one patient) and Klebsiella oxytoca in two patients (antibiotic-resistant in one patient). Faecal concentration of Group D Streptococcus was significantly increased at the end of therapy (basal mean 7.7 +/- 1.2 log CFU vs post treatment mean 9.6 +/- 0.5 log CFU, p < 0.05) while the faecal concentration of anaerobic flora and Candida albicans showed no change. CONCLUSIONS: Results of this study demonstrate the efficacy of oral ciprofloxacin as a selective intestinal decontaminant and ciprofloxacin 250 mg/day is the recommended dose for maintaining Selective Intestinal Decontamination. However, the risks of inducing antibiotic resistance in Gram-negative flora and promoting overgrowth of Gram-positive flora must be carefully considered in all patients chronically treated with oral quinolones.


Subject(s)
Anti-Infective Agents/therapeutic use , Antibiotic Prophylaxis , Ciprofloxacin/therapeutic use , Liver Cirrhosis/microbiology , Administration, Oral , Anti-Infective Agents/administration & dosage , Bacterial Infections/prevention & control , Ciprofloxacin/administration & dosage , Feces/microbiology , Female , Gram-Negative Bacteria/isolation & purification , Gram-Positive Bacteria/isolation & purification , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/drug therapy , Male , Middle Aged , Statistics, Nonparametric
11.
Eur J Clin Microbiol Infect Dis ; 21(12): 849-55, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12525919

ABSTRACT

The epidemiology of bacterial pathogens causing bloodstream infection was studied in 16 hospitals in Lombardy (northern Italy) over a 2-year period (1999 and 2000). Overall, 2924 microorganisms causing significant bacteremia were collected. The most frequent isolates were Escherichia coli ( n=663; 22.7%), Staphylococcus aureus ( n=534; 18.3%), Staphylococcus epidermidis ( n=242; 8.2%), and Pseudomonas aeruginosa ( n=176; 6.0%). Unlike Escherichia coli, which was usually acquired from the community, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa were usually acquired in hospitals. Rates of resistance to oxacillin and its associated traits were significantly higher among hospital-acquired staphylococci as compared to those of isolates from the community. Escherichia coli was highly susceptible to extended-spectrum cephalosporins, with a very low percentage of strains producing extended-spectrum ss-lactamases (ESBLs). On the contrary, production of ESBL appeared to be an important mechanism of resistance among nosocomial isolates of Klebsiella pneumoniae. Resistance to ciprofloxacin was widespread in several members of the family Enterobacteriaceae, with rates often exceeding 10%. Moreover, with regard to ciprofloxacin, there were no significant differences between rates of resistance among Enterobacteriaceae causing hospital-acquired infections versus those causing community-acquired infections. Multidrug resistance was commonly observed in Pseudomonas aeruginosa, indicating the need for new antimicrobial agents that are more active against nonfermentative gram-negative bacteria. In conclusion, epidemiological studies of the prevalence and antimicrobial susceptibility patterns of blood isolates in northern Italy appear to provide useful information for both empirical treatment of suspected infections and better management of patients.


Subject(s)
Bacterial Infections/epidemiology , Bacterial Infections/microbiology , Drug Resistance, Multiple, Bacterial , Adult , Anti-Bacterial Agents/pharmacology , Bacteremia/epidemiology , Bacteremia/microbiology , Child , Female , Gram-Negative Bacteria/drug effects , Gram-Positive Bacteria/drug effects , Hospitals , Humans , Italy/epidemiology , Male , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL